In an era where pharmaceutical and life sciences manufacturing is becoming faster, smarter, and more connected, one process continues to stand out for all the wrong reasons: line clearance.
At Catalyx, we’ve been tracking the evolution of this critical step through our Global Line Clearance Benchmark, and the findings reveal a fascinating — and sometimes frustrating — story about how digital transformation is unfolding on the factory floor.
Two Years of Change — and What’s Stayed the Same
When we first released our 2023 Line Clearance Benchmark, the industry was at a tipping point. Manufacturers were investing heavily in automation, yet manual line clearance remained a constant source of deviation, delay, and downtime.
Now, as we release our updated 2025 findings, the picture looks more complex. There has been real progress — but also persistent gaps that show how difficult true transformation can be in a regulated environment.
What the Data Shows
Without revealing the full dataset, three statistics from the 2025 Catalyx Global Line Clearance Benchmark tell a clear story about where the industry stands today:
- 68% of manufacturers reported at least one line clearance deviation in the past year.
- 74% pointed to rogue components as the top cause of those failures.
- Nearly one in four said line clearance still takes more than two hours per changeover.
On the surface, these numbers are similar to what we saw in 2023 — but the conversations behind them have changed. Manufacturers aren’t questioning if they should automate anymore; they’re asking how soon and how far they can go without compromising compliance.
Why Line Clearance Still Matters
In many ways, line clearance has become a proxy for how prepared a company is for the next phase of digital manufacturing. Facilities that have digitized this step are seeing fewer deviations, faster changeovers, and stronger audit outcomes. Those that haven’t are finding that manual methods are increasingly hard to sustain under the weight of modern regulatory and operational demands.
Beyond our own data, the industry context reinforces this trend. The push toward connected manufacturing, the growing influence of regulatory expectations around data integrity, and the workforce challenges faced by many plants are converging. Together, they’re creating an environment where efficiency and compliance can no longer be traded off against each other.
What Comes Next
Catalyx remains committed to supporting the evolution of process maturity in line changeovers. We believe a new standard is within reach, one that increases throughput, strengthens compliance, and gives teams the confidence to scale.
The benchmarks in this report are designed to help manufacturers assess their current state and chart a smarter path forward. Catalyx has partnered with leading pharma, biotech, and medical device organizations to tackle these challenges head-on, combining deep operational insight with proven automation and compliance expertise.
Download the Catalyx Global Line Clearance Benchmark Report to access the full insights and see how forward-thinking manufacturers are setting new standards for faster, safer, and more reliable operations.